Try
TransMedics Group, Inc.
TMDXUnited States
55 filed reports · 414 financial concepts · 0 earnings calls · 0 media appearances
Filed reports
55 reports · Mar 2019 to Jun 2026Each report counts once it has at least one extracted financial fact. Also extracted from these reports: 62 guidance figures.
| Report type | Reports | Facts | Periods |
|---|---|---|---|
| Current · 8-KSEC EDGAR | 25 | 60 | Mar 2019 to Jun 2026 |
| Quarterly · 10-QSEC EDGAR | 23 | 3,376 | Mar 2019 to Jun 2026 |
| Annual · 10-KSEC EDGAR | 7 | 2,896 | Dec 2019 to Dec 2025 |
Documents
| Period | Type | Period end | Published | Facts | Source |
|---|---|---|---|---|---|
| FY2026 Q2 | 8-K | Jun 30, 2026 | Aug 4, 2026 | 2 | Open |
| FY2026 Q2 | 10-Q | Jun 30, 2026 | Aug 4, 2026 | 365 | Open |
| FY2026 Q1 | 8-K | Mar 31, 2026 | May 5, 2026 | 2 | Open |
| FY2026 Q1 | 10-Q | Mar 31, 2026 | May 5, 2026 | 219 | Open |
| FY2025 Q4 | 8-K | Dec 31, 2025 | Feb 24, 2026 | 4 | Open |
| FY2025 | 10-K | Dec 31, 2025 | Feb 24, 2026 | 813 | Open |
| FY2025 Q3 | 10-Q | Sep 30, 2025 | Oct 29, 2025 | 219 | Open |
| FY2025 Q3 | 8-K | Sep 30, 2025 | Oct 29, 2025 | 2 | Open |
| FY2025 Q2 | 10-Q | Jun 30, 2025 | Jul 30, 2025 | 132 | Open |
| FY2025 Q2 | 8-K | Jun 30, 2025 | Jul 30, 2025 | 2 | Open |
| FY2025 Q1 | 10-Q | Mar 31, 2025 | May 8, 2025 | 133 | Open |
| FY2025 Q1 | 8-K | Mar 31, 2025 | May 8, 2025 | 2 | Open |
Financial data
414 concepts · 6,332 factsEach concept is one reported line item or metric. The count is how many values of it are held, across the periods shown.
Financial402 concepts · 5,726 facts · Dec 2017 to Jul 2026
- Net income loss47 · Mar 2018 to Jun 2026
- Other comprehensive income loss foreign currency transaction and translation adjustment net of tax46 · Mar 2018 to Jun 2026
- Stockholders equity (US GAAP)45 · Dec 2017 to Jun 2026
- Cash cash equivalents restricted cash and restricted cash equivalents44 · Dec 2017 to Jun 2026
- Comprehensive income net of tax44 · Mar 2018 to Jun 2026
- Gross profit (US GAAP)44 · Mar 2018 to Jun 2026
- Operating income loss44 · Mar 2018 to Jun 2026
- Profit loss44 · Mar 2018 to Jun 2026
- Revenue44 · Mar 2018 to Jun 2026
- Cost of revenue (US GAAP)43 · Mar 2018 to Jun 2026
- Nonoperating income expense43 · Mar 2018 to Jun 2026
- Operating expenses (US GAAP)43 · Mar 2018 to Jun 2026
- Research and development expense43 · Mar 2018 to Jun 2026
- Selling general and administrative expense43 · Mar 2018 to Jun 2026
- Stock issued during period value stock options exercised43 · Mar 2018 to Jun 2026
- Allocated share based compensation expense42 · Mar 2018 to Jun 2026
- Other comprehensive income loss net of tax42 · Mar 2018 to Dec 2025
- Cash cash equivalents restricted cash and restricted cash equivalents period increase decrease including exchange rate effect40 · Mar 2018 to Jun 2026
- Depreciation depletion and amortization40 · Mar 2018 to Jun 2026
- Effect of exchange rate on cash cash equivalents restricted cash and restricted cash equivalents40 · Mar 2018 to Jun 2026
- Increase decrease in accounts payable40 · Mar 2018 to Jun 2026
- Increase decrease in accounts receivable40 · Mar 2018 to Jun 2026
- Increase decrease in accrued liabilities and other operating liabilities40 · Mar 2018 to Jun 2026
- Increase decrease in inventories40 · Mar 2018 to Jun 2026
Product6 concepts · 240 facts · Mar 2018 to Jun 2026
- Revenue178 · Mar 2018 to Jun 2026
- Cost of revenue (US GAAP)48 · Dec 2020 to Jun 2026
- Net product revenue6 · Dec 2020 to Dec 2025
- Capitalized computer software period increase decrease3 · Dec 2021 to Dec 2023
- Revenue from contracts with customers (excluding tax)3 · Dec 2020 to Dec 2022
- Revenue (excluding assessed tax)2 · Dec 2023 to Dec 2024
Segment1 concepts · 192 facts · Dec 2021 to Jun 2026
- Revenue192 · Dec 2021 to Jun 2026
Geography1 concepts · 110 facts · Mar 2018 to Jun 2023
- Revenue110 · Mar 2018 to Jun 2023
Guidance3 concepts · 62 facts · Jun 2019 to Aug 2026
- Revenue Guidance48 · Jun 2019 to Aug 2026
- Revenue Growth Guidance12 · Feb 2023 to Feb 2026
- Effective Tax Rate Guidance2 · Aug 2026
KPI1 concepts · 2 facts · Jan 2026 to Mar 2026
- Properties Acquired2 · Jan 2026 to Mar 2026
Segments
542 factsFigures broken down by business line, region, product or another axis the company reports on.
Product or service12 members · 240 facts
- Product57 · Dec 2020 to Jun 2026
- Service48 · Dec 2020 to Jun 2026
- Ocs Heart Product23 · Mar 2018 to Sep 2022
- Ocs Liver Product23 · Mar 2018 to Sep 2022
- Ocs Lung Product23 · Mar 2018 to Sep 2022
- Heart Product14 · Dec 2020 to Jun 2023
- Lung Product14 · Dec 2020 to Jun 2023
- Service Unrelated To OCS Transplant12 · Dec 2023 to Jun 2026
- Unrelated To Ocs Transplant12 · Sep 2022 to Mar 2025
- Liver Product9 · Dec 2020 to Jun 2023
- Internal Use3 · Dec 2021 to Dec 2023
- Product2 · Dec 2023 to Dec 2024
Statement business segments1 member · 192 facts
- Ocs Transplant Revenue192 · Dec 2021 to Jun 2026
Statement geographical8 members · 110 facts
- US27 · Mar 2018 to Jun 2023
- Other Countries23 · Mar 2018 to Jun 2023
- Non Us And Uk17 · Mar 2019 to Jun 2022
- GB16 · Mar 2018 to Sep 2021
- Non Us10 · Mar 2018 to Dec 2019
- DE9 · Mar 2018 to Dec 2019
- AU5 · Mar 2018 to Sep 2019
- IT3 · Mar 2018 to Jun 2019
Text from filings
Management commentary and risk factors, extracted from SEC filings only.
No commentary or risk-factor text for this company.
Earnings calls
Transcripts with management claims and analyst questions, one per fiscal period.
No earnings-call transcripts for this company.
Executive media
Podcasts, interviews and conference appearances by the company's executives, with their claims.
No media appearances for this company.
Reports are counted as filed reports with at least one served fact. Counts are read from the database (last read Oct 16, 2026) and refreshed every few hours.